SCHEMBL10052270

SCHEMBL10052270

Cc1ccc(C(=O)C(C(=O)c2ccc(C)cc2)[C@H](CN=O)c2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
CES2 O00748 2/20 0.43
CES1 P23141 2/20 0.43
NPSR1 Q6W5P4 3/20 0.43
CYP3A4 P08684 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
LMNA P02545 7/20 0.41
TP53 P04637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 2/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2760476 0.94 NPC1 (0.44) MEN1KMT2ARAB9ANPC1CES2
SCHEMBL2760475 0.89 TDP1 (0.50) RAB9ANPC1CES2CES1NPSR1
SCHEMBL2760486 0.83 LMNA (0.51) MEN1KMT2ARAB9ANPC1CES2
SCHEMBL2760487 0.79 CES2 (0.43) MEN1KMT2ARAB9ANPC1CES2
SCHEMBL10051875 0.78 L3MBTL1 (0.52) MEN1KMT2ARAB9ANPC1CES2
SCHEMBL2760474 0.78 MTNR1A (0.46) MEN1KMT2ARAB9ANPC1CES2
SCHEMBL221654 0.77 GAA (0.42) MEN1KMT2ARAB9ANPC1CES2
SCHEMBL2760472 0.75 TDP1 (0.37) RAB9ANPC1CES2CES1CYP3A4
SCHEMBL15105761 0.73 L3MBTL1 (0.73) MEN1KMT2ARAB9ANPC1CES2
SCHEMBL2760490 0.72 POLB (0.50) MEN1KMT2ARAB9ANPC1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004424-A1 MICHAEL REACTION WITH RECOVERY OF THE CATALYST NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004424-A1 MICHAEL REACTION WITH RECOVERY OF THE CATALYST CYP2E1, CYP11B2, CYP11B1 MEN1 415/4885KMT2A 3060/4885RAB9A 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.